Precision Neuroscience Raises $250 Million Series D, Funding Next FDA Steps For Layer 7

Precision Neurosciences raised $250 million in an oversubscribed Series D financing round, adding fresh capital to a brain-computer interface company that is trying to turn clinical and regulatory progress into a commercial position. The company said it has now raised $430 million to date.

According to Precision, that funding has helped it build what it describes as the largest clinical footprint in the BCI arena, with more than 100 patient procedures conducted in 18 medical institutions. The latest round will be used to expand the clinical program, advance Layer 7 through the next stages of FDA review and build infrastructure needed for commercialization.

Why investors backed this round

BCI remains a technically ambitious area, but this raise suggests investors are rewarding execution markers that are easier to measure than long-range promises. Precision already won FDA 510(k) approval in March 2025 for its Layer 7 cortical interface, which records, monitors and stimulates brain electrical activity with a temporary implant for up to 30 days. The system was developed in partnership with Medtronic.

That matters because financing in medtech tends to improve when a company can point to more than prototype progress. Precision is pairing capital with a defined regulatory position, a network of 18 institutions and procedural experience in more than 100 patients. CEO Michael Mager said the next phase of BCI will be defined by more than technology alone, adding that the company has built the clinical network, regulatory position and manufacturing base that leadership in the field requires while putting safety at the center of product design.

The commercial signal

The Series D was co-led by Pershing Square Inc., the Ackman Oxman Institute and an undisclosed leading life sciences investment fund. Additional investors included the Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures and JSL Health Capital.

The financing arrives as the BCI field is broadening beyond research milestones toward regulated products. The report also points to a recent study showing BCI training, which uses feedback from electrical activity in the brain, could be used to improve cognitive function in neuropsychiatric patients with Parkinson’s disease, multiple sclerosis, dementia and traumatic brain injury.

The immediate takeaway is not that BCI has become routine care. It is that investors are still willing to fund companies in the category when they can show a combination of clinical access, FDA progress and a plan for commercialization rather than novelty alone.